Hepatopancreatobiliary Carcinoma — Trials

Hepatopancreatobiliary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

5,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,360
Recruiting: 790
Ph III recruiting: 74
Growth YoY: +10.6%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (645)

clinicaltrialsPublishedShowing 651–681 of 681 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06389422	Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis	recruiting	Phase 2	30	Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER	1	Apr 29, 2024	clinicaltrials
NCT06360042	Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC	recruiting	Phase 2	111	Peking University Cancer Hospital & InstituteOTHER	1	Apr 22, 2024